The U.S. FDA denied Lexicon Pharmaceuticals Inc’s appeal against the rejection of its add-on treatment for type 1 diabetes, marking the company’s third major setback this year and sending its shares plunging 18% on Monday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,